TECNIS Synergy Review

What TECNIS Synergy is

TECNIS Synergy is a presbyopia-correcting IOL from Johnson & Johnson Surgical Vision, approved by the FDA on April 28, 2021 under PMA P980040, supplement S124. The primary model is ZFR00V (with a Simplicity delivery-system variant, DFR00V), plus a toric line (ZFW150/225/300/375 and the corresponding DFW models) for patients with meaningful corneal astigmatism. Optically, it combines a continuous, EDOF-style extended-range profile with a diffractive structure carrying a relatively low near add — the manufacturer's stated aim is to cover distance, intermediate, and near vision from one lens, rather than relying on a monofocal-style single focal point or a classic trifocal's three discrete zones.

What it looks like

The image below is reproduced from the lens's own FDA regulatory filing, not manufacturer marketing artwork, so what is shown is exactly what the FDA reviewed and approved.

Source: FDA SSED, PMA P980040/S124, Figure 1

Where the data on this page comes from

As with our other model reviews, every figure below comes from the lens's FDA Summary of Safety and Effectiveness Data (SSED) — the public document FDA publishes alongside approval, drawn from the same pivotal clinical trial the manufacturer used to obtain clearance (PMA P980040/S124, approved April 28, 2021: 297 enrolled patients, 272 implanted — 135 Synergy, 137 with a monofocal control lens — across 15 U.S. sites, followed to 6 months). Every number is cited to its table in that document so it can be checked directly.

One gap is worth flagging upfront: the SSED presents its defocus curve and contrast-sensitivity results only as graphs, not as data tables — a common practice in these documents. That means we can report the narrative conclusions FDA and the manufacturer drew from those graphs, but we can't reproduce exact per-diopter or per-spatial-frequency numbers the way we can for the visual-acuity and questionnaire tables, which are published as text. Where a claim below relies on a graph rather than a table, we say so explicitly rather than estimating numbers we can't verify.

Visual acuity by distance

Unlike some other lenses in this category, Synergy's pivotal trial reported distance-corrected visual acuity at all three functional distances — distance, intermediate, and near — which lets us show a complete picture.

The pattern here is different from a monofocal lens or from lenses that only extend intermediate range: Synergy's advantage over the control widens as the task moves closer, and near vision — traditionally the weakest point for EDOF-style designs — shows the largest gap in this dataset. Distance vision was effectively equivalent between the two groups, which is the expected trade-off baseline for a lens spreading light across additional focal points.

Depth of focus and contrast sensitivity — what the graphs show

The SSED states that Synergy "achieved at least 0.2 logMAR visual acuity from 0.0 D to -2.5 D of defocus and sustained it beyond -3.0 D" — meaning a wide continuous range stayed reasonably sharp, per the document's own defocus-curve figures (Figures 8–12). No per-diopter numeric table accompanies this statement in the SSED, so we're reporting it as the source document's own summary rather than a reconstructed curve.

On contrast sensitivity, the SSED's narrative conclusion is that sensitivity was "generally lower for the Synergy group than the control group... especially under extremely high glare conditions," while stating this difference was "not found to be associated with clinically significant impact." Again, this comes from graphs (contrast-sensitivity figures around pp. 28–31 of the SSED) rather than a published numeric table, so we're summarizing the document's own stated conclusion rather than presenting exact figures we can't independently verify.

Spectacle independence

This is the largest and most consistent gap in the entire dataset, and it reflects the lens's core design goal — reducing glasses dependence across all distances, not just one. It's a patient-reported questionnaire result, not an objective acuity measurement, so it reflects subjective experience rather than a clinical test.

Visual disturbances (halos, glare, starbursts)

This is the clearest trade-off in the dataset, and it runs in the opposite direction from the spectacle-independence result above — both are real, and neither cancels the other out. Halos in particular were reported by roughly 1 in 5 Synergy patients versus roughly 1 in 25 control patients, a substantially larger gap than we found when reviewing other lenses in this category with a smaller near-vision add. On the follow-up "how bothered are you" questionnaire (Table 17), 3.8% of Synergy patients rated halos as causing extreme bother and 5.3% rated starbursts as extreme, versus 0% of control patients for both — small percentages in absolute terms, but consistently higher than the control group across every disturbance measured.

Who this lens may suit

This dataset suggests Synergy tends to suit patients who most value broad spectacle independence across distance, intermediate, and near tasks together, and who are willing to accept a meaningfully higher chance of halos and night glare in exchange — particularly patients who don't drive frequently after dark or who are less bothered by nighttime visual phenomena generally. Patients highly sensitive to glare, or with occupations demanding frequent night driving, may want to discuss this trade-off in detail with their surgeon before choosing this lens over a lower-add or non-diffractive alternative. As always, this is a conversation for your surgeon based on your own eye measurements and health, not something a general article can settle.

How it compares

Synergy sits within the full-range / extended-vision category — lenses aiming to cover distance, intermediate, and near from a single implant, generally through diffractive designs that split light across multiple focal points. For the category-level trade-offs (versus standard monofocal, enhanced monofocal, and non-diffractive EDOF lenses), see Full Range / Trifocal / Multifocal. For a broader look at why some patients report dissatisfaction with presbyopia-correcting lenses in this category generally, see Why Do Some Presbyopia-Correcting IOL Patients Report Dissatisfaction?

A note on how manufacturers present this same data

As with other lenses in this category, it's worth understanding how this same underlying trial tends to be repackaged for sales materials. A common pattern is to lead with the most favorable single metric — such as the spectacle-independence figure shown above, which is genuinely strong — while presenting visual-disturbance data, when shown at all, using different comparison groups, older competitor products, or bench-optics measurements rather than the same patient-reported clinical outcomes shown side-by-side here. Materials distributed to prescribers frequently draw on internal "Data on File" studies that aren't independently published or peer-reviewed, and are often explicitly restricted to healthcare-professional audiences rather than intended for patients to read directly. We've used the public FDA record instead, and presented the favorable and unfavorable results from the same trial together, because a patient weighing this trade-off needs both halves of the picture at once.

A note on this review

This page is educational content, not a clinical trial result and not a personal recommendation. Every figure is sourced directly from the FDA's public SSED for PMA P980040/S124 and cited by table or figure number so you can verify it yourself; where the source document presents a result only as a graph rather than a data table, we've said so rather than estimating numbers we can't confirm. Actual outcomes vary from patient to patient, and the right lens for you can only be determined by a qualified ophthalmic surgeon based on your individual eye measurements and health history.